PRCT
PROCEPT BioRobotics Corporation
$21.97
+1.06
(+5.07%)
Mkt Cap
1.25B
Volume
1,277,723
52W Range
16.665-41.51
Sector
Healthcare
Beta
0.89
EPS (TTM)
-1.94 USD
P/E Ratio
-18.29
Revenue (TTM)
337.34M USD
Rev Growth (5Y)
+109.1%
EPS Growth (5Y)
N/A
Company Description
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 308.05M | 224.50M | 136.19M | 75.01M | 34.47M | 7.72M | 6.17M |
| Net Income | (95.57M) | (91.41M) | (105.90M) | (87.15M) | (59.85M) | (53.02M) | (41.98M) |
| EPS | -1.72 | -1.75 | -2.24 | -1.96 | -1.37 | -1.51 | -1.25 |
| Free Cash Flow | (58.34M) | (103.62M) | (133.21M) | (83.03M) | (57.93M) | (48.58M) | (51.43M) |
| FCF / Share | -1.05 | -1.99 | -2.82 | -1.87 | -1.33 | -1.38 | -1.53 |
| Operating CF | (48.98M) | (99.21M) | (108.00M) | (80.38M) | (57.33M) | (48.34M) | (43.82M) |
| Total Assets | 508.08M | 534.02M | 404.72M | 309.33M | 337.02M | 125.97M | 61.99M |
| Total Debt | 78.48M | 80.25M | 79.20M | 77.32M | 54.10M | 54.76M | 23.22M |
| Cash & Equiv | 286.50M | 333.73M | 257.22M | 222.64M | 304.32M | 100.13M | 42.02M |
| Book Value | 365.87M | 402.22M | 280.75M | 197.07M | 267.09M | 60.96M | 29.23M |
| Return on Equity | -0.26 | -0.23 | -0.38 | -0.44 | -0.22 | -0.87 | -1.44 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 94.50M | 83.13M | 76.38M | 83.33M | 79.18M | 69.16M | 68.24M | 58.37M | 53.35M | 44.54M | 43.58M | 35.10M |
| Net Income | (26.86M) | (31.64M) | (29.84M) | (21.41M) | (19.58M) | (24.74M) | (18.86M) | (20.97M) | (25.63M) | (25.96M) | (27.50M) | (24.62M) |
| EPS | -0.47 | -0.56 | -0.53 | -0.38 | -0.35 | -0.45 | -0.35 | -0.40 | -0.50 | -0.51 | -0.54 | -0.51 |
| Free Cash Flow | (63.24M) | (41.04M) | (12.18M) | (9.50M) | (17.84M) | (18.82M) | (33.56M) | (19.05M) | (16.78M) | (34.23M) | (33.51M) | (24.72M) |
| FCF / Share | -1.12 | -0.73 | -0.22 | -0.17 | -0.32 | -0.34 | -0.62 | -0.37 | -0.33 | -0.67 | -0.66 | -0.51 |
| Operating CF | (57.38M) | (38.13M) | (10.33M) | (6.63M) | (15.04M) | (16.98M) | (32.39M) | (18.80M) | (15.74M) | (32.29M) | (24.79M) | (18.94M) |
| Total Assets | 479.35M | 487.06M | 508.08M | 511.54M | 513.05M | 519.38M | 534.02M | 374.14M | 374.35M | 382.90M | 404.72M | 421.12M |
| Total Debt | 77.50M | 78.00M | 78.48M | 78.93M | 79.37M | 79.81M | 80.25M | 80.64M | 81.02M | 81.39M | 79.20M | 79.74M |
| Cash & Equiv | 227.91M | 245.64M | 286.50M | 294.28M | 302.72M | 316.21M | 333.73M | 196.76M | 214.09M | 225.58M | 257.22M | 287.86M |
| Book Value | 340.07M | 347.67M | 365.87M | 380.28M | 385.80M | 389.16M | 402.22M | 241.22M | 251.78M | 264.05M | 280.75M | 299.36M |
| Return on Equity | -0.08 | -0.09 | -0.08 | -0.06 | -0.05 | -0.06 | -0.05 | -0.09 | -0.10 | -0.10 | -0.10 | -0.08 |
PRCT News
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP
Kaplan Fox Urges Investors of PROCEPT BioRobotics Corporation (PRCT) to Contact the Firm Before the Securities Class Action Deadline on September 22, 2026
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2026 in PROCEPT BIOROBOTICS CORPORATION Lawsuit - PRCT
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against PROCEPT BioRobotics Corporation (PRCT)
Kaplan Fox Notifies Investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) of the Lead Plaintiff Deadline on September 22, 2026
PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
PRCT FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages PROCEPT BioRobotics Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - PRCT
Bragar Eagel & Squire, P.C Urges PROCEPT BioRobotics Corporation Investors to Contact the Firm Seeking Lead Plaintiff Role Before September 22nd
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in PROCEPT BioRobotics Corporation of Class Action Lawsuit and Upcoming Deadlines – PRCT
Portnoy Law Firm Announces Class Action on Behalf of PROCEPT BioRobotics Corporation Investors